Title: Retired President of Lilly Research Labs and Head of Research and Development
Company: Eli Lilly and Company (Now Lilly)
Location: Fort Lauderdale, Florida, United States
Jan M. Lundberg, Retired President of Lilly Research Labs and Head of Research and Development at Eli Lilly and Company (Now Lilly), has been recognized by Marquis Who’s Who Top Scientists for dedication, achievements, and leadership in Pharmaceuticals.
Dr. Lundberg enjoyed a long and successful career in the pharmaceutical sector that spanned several decades. Retiring in 2018, he served as the president of Lilly Research Labs and the head of research and development at Eli Lilly and Company (now Lilly). Dr. Lundberg’s career at the organization was marked by significant contributions to developing several new medications, thus positioning Lilly as a leader in pharmaceutical market capitalization.
Since his retirement, Dr. Lundberg has been involved in consulting and has begun serving on various boards. His focus has primary focus has been on more prevalent diseases that significantly affect individuals and society, such as diabetes, Alzheimer’s disease, autoimmune disorders, and cancer.
While Dr. Lundberg was employed at Eli Lilly and Company, the company was facing a potential takeover by Pfizer with a share price of just $30. One year later, the organization raised its share prices to over $900 with internal research and development initiatives. Dr. Lundberg was grateful to be a part of such a significant success that positioned the organization for future success and stability.
Before joining Eli Lilly and Company, Dr. Lundberg was the global head of discovery research at AstraZeneca from 1999 to 2009. He also served as the head of preclinical research at Astra AB between 1996 and 1999. Earlier in his career, Dr. Lundberg found success as a professor at his alma mater, Karolinska Institutet, one of the world´s leading medical universities in Solna, Sweden, from 1993 to 1996. Moreover, he co-founded Aerocrinen AB, a biotechnology company.
Highly educated, Dr. Lundberg obtained a Doctor of Philosophy in pharmacology from Karolinska Institutet. He also completed coursework at the University of Gothenburg, an esteemed institution in Gothenburg, Sweden. His education has been instrumental in his pharmaceutical career, making him well-prepared for a future in this sector.
In addition to his full-time commitments, Dr. Lundberg served on boards for AstraZeneca, Lilly, Metabolon, IAG, Anocca, and TB Alliance, among others. As such, he has provided his insight and expertise in various aspects of the industry as a respected industry leader.
Among many noteworthy accomplishments throughout his tenured career, Dr. Lundberg was involved in over 200 candidate drugs and 30 approved products across multiple therapeutic areas, including Brilinta, Iressa, Nexium, Taltz, Trulicity, and Tirzepatide (Mounjaro). He was also involved in positive phase 3 for Donanemab in Alzheimer’s disease. As a seasoned researcher, he has authored over 500 scholarly articles in various peer-reviewed journals, disseminating his extensive research. Dr. Lundberg’s success in discovering and developing new medicines has been a cornerstone of his career.
In 2003, Dr. Lundberg received an Honorary Doctorate from Uppsala University in Sweden for his accomplishments. He also received the Jahre Prize in 1988 and a Fernström Prize in 1993. Dr. Lundberg attributes his success to the importance of effective teamwork, a solid foundation of skills and scientific knowledge, and patience with a long-term perspective, which are essential in his field. In the years ahead, Dr. Lundberg aims to contribute more medicines to meet unmet medical needs.
For more information, please visit:
Contact Dr. Lundberg:
